Related Experiment Videos

Meta-analysis of chemotherapy in head and neck cancer: individual patient data vs literature data

J P Pignon, J Bourhis

British Journal of Cancer

|October 1, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

ESMO open·2026

Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025

International guidelines for the delineation of the postoperative clinical target volumes (CTV) for parotid and submandibular gland cancers.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025

[Proposal for the delineation of postoperative primary clinical target volumes in maxillary sinus and nasal cavity cancers].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

See all related articles